Last reviewed · How we verify
Tetanus Diphtheria Vaccine
The tetanus-diphtheria vaccine stimulates the immune system to produce antibodies against toxins produced by Clostridium tetani and Corynebacterium diphtheriae bacteria.
The tetanus-diphtheria vaccine stimulates the immune system to produce antibodies against toxins produced by Clostridium tetani and Corynebacterium diphtheriae bacteria. Used for Prevention of tetanus, Prevention of diphtheria.
At a glance
| Generic name | Tetanus Diphtheria Vaccine |
|---|---|
| Also known as | Td |
| Sponsor | Nationwide Children's Hospital |
| Drug class | Toxoid vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated toxoids (chemically inactivated bacterial toxins) from tetanus and diphtheria pathogens. When administered, these toxoids trigger the adaptive immune response, causing B cells to produce specific antibodies (antitoxins) that neutralize the actual toxins if infection occurs. This provides long-term immunity against both tetanus and diphtheria diseases.
Approved indications
- Prevention of tetanus
- Prevention of diphtheria
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Fatigue or malaise
- Headache
- Myalgia
Key clinical trials
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents) (PHASE1)
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy (PHASE4)
- ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (PHASE1)
- Safety Monitoring of Boostagen® Vaccine in Thailand
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- Long-Term PF-06651600 for the Treatment of Alopecia Areata (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tetanus Diphtheria Vaccine CI brief — competitive landscape report
- Tetanus Diphtheria Vaccine updates RSS · CI watch RSS
- Nationwide Children's Hospital portfolio CI